Recurrence risk after transient ischemic attack (TIA) or ischemic stroke (IS) ranges from 5 to
20% per year [1–3]. The risk is highest immediately after the first event [4–6]. Numerous trials …

Background and Purpose—Disabling stroke is costly and considered by some patients a
fate worse than death. We aimed to determine whether clopidogrel reduces the rate and …

Opinion statement Though antiplatelet agents are the mainstay of antithrombotic therapy for
secondary prevention of noncardioembolic cerebral ischemic events, the efficacy of …

Background The current guidelines recommend various antiplatelet agents used alone or in
combination for secondary prevention of noncardioembolic stroke. Objective The purpose of …

Background: Combination treatment with clopidogrel and aspirin is not currently
recommended for secondary prevention of stroke, but its superior effect to aspirin alone has …

Antiplatelet therapy is universally recommended for the prevention of recurrent events in
patients with noncardioembolic ischaemic stroke or transient ischaemic attack (TIA), acute …

Stroke is the leading cause of adult disability and dependency in western society. Following
stroke, the risk of myocardial infarction (MI) is increased by a factor of around 2–3 compared …

The performance of randomized clinical trials provides evidence-based medical information
to clinicians and impacts on day-to-day treatment decisions. Many secondary stroke …

Background Antiplatelet therapies for secondary prevention of ischemic stroke or transient
ischemic attack (TIA) is a highly active research topic with five critical drugs obtained by …

Background and Purpose—The goal of this study was to examine the influence of
preexisting symptomatic atherosclerotic disease on subsequent ischemic event rates and …